Literature DB >> 3493144

Temporal regulation of influenza hemagglutinin expression in vaccinia virus recombinants and effects on the immune response.

B E Coupar, M E Andrew, G W Both, D B Boyle.   

Abstract

Regulation of the expression of influenza A/PR/8/34 hemagglutinin (HA) by the vaccinia virus promoters PF (early), P7.5 (early and late) and PL11 (late) has been demonstrated using HA-vaccinia recombinant viruses VV-PR8-HA3, VV-PR8-HA6 and VV-PR8-HA, respectively. Levels of HA on the surface of VV-PR8-HA3 (PF)-infected cells were lower than with either VV-PR8-HA6 (P7.5) or VV-PR8-HA8 (PL11). Expression of HA under the control of the late promoter PL11 was inhibited in the absence of DNA replication. All three recombinant viruses stimulated a specific antibody response in mice which was dependent on the presence of infectious virus. Recognition of HA by cytotoxic T lymphocytes (CTL) was assessed by the ability of the viruses to stimulate naive precursors in vivo, to restimulate primed CTL in vitro and by target cell recognition. HA expressed under the control of either of the promoters with early function (PF or P7.5) was recognized by CTL when VV-PR8-HA3 or VV-PR8-HA6 were used to prime or restimulate splenocytes or to infect target cells. On the other hand, HA expressed by VV-PR8-HA8 (PL11) failed to prime for a CTL response in naive CBA/H mice, was ineffective at restimulation of primed splenocytes and failed to produce target cells for recognition by specific CTL. However, in BALB/c mice VV-PR8-HA8 did prime for a specific CTL response. These studies show that HA synthesized early in infection was recognized by both B and T cells while HA expressed after DNA replication was not generally recognized by T cells. The implications of the observations with the late promoter with respect to the use of late promoters in potential vaccinia virus-based vaccines are considered.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3493144     DOI: 10.1002/eji.1830161203

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  44 in total

1.  Immediate-early expression of a recombinant antigen by modified vaccinia virus ankara breaks the immunodominance of strong vector-specific B8R antigen in acute and memory CD8 T-cell responses.

Authors:  Karen Baur; Kay Brinkmann; Marc Schweneker; Juliane Pätzold; Christine Meisinger-Henschel; Judith Hermann; Robin Steigerwald; Paul Chaplin; Mark Suter; Jürgen Hausmann
Journal:  J Virol       Date:  2010-06-10       Impact factor: 5.103

2.  Recognition of the Epstein-Barr virus-encoded nuclear antigens EBNA-4 and EBNA-6 by HLA-A11-restricted cytotoxic T lymphocytes: implications for down-regulation of HLA-A11 in Burkitt lymphoma.

Authors:  R Gavioli; P O De Campos-Lima; M G Kurilla; E Kieff; G Klein; M G Masucci
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-01       Impact factor: 11.205

Review 3.  The next wave of recombinant and synthetic anticancer vaccines.

Authors:  K R Irvine; N P Restifo
Journal:  Semin Cancer Biol       Date:  1995-12       Impact factor: 15.707

4.  Increased expression in vivo and in vitro of foreign genes directed by A-type inclusion body hybrid promoters in recombinant vaccinia viruses.

Authors:  S Funahashi; S Itamura; H Iinuma; K Nerome; M Sugimoto; H Shida
Journal:  J Virol       Date:  1991-10       Impact factor: 5.103

Review 5.  Initiation of primary anti-vaccinia virus immunity in vivo.

Authors:  Matthew A Fischer; Christopher C Norbury
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

6.  The immunologist's grail: vaccines that generate cellular immunity.

Authors:  M A Liu
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-30       Impact factor: 11.205

7.  The 22,000-kilodalton protein of respiratory syncytial virus is a major target for Kd-restricted cytotoxic T lymphocytes from mice primed by infection.

Authors:  P J Openshaw; K Anderson; G W Wertz; B A Askonas
Journal:  J Virol       Date:  1990-04       Impact factor: 5.103

8.  Long-term T cell memory to human leucocyte antigen-A2 supertype epitopes in humans vaccinated against smallpox.

Authors:  N D Ostrout; M M McHugh; D J Tisch; A M Moormann; V Brusic; J W Kazura
Journal:  Clin Exp Immunol       Date:  2007-05-04       Impact factor: 4.330

9.  Constructions of vaccinia virus A-type inclusion body protein, tandemly repeated mutant 7.5 kDa protein, and hemagglutinin gene promoters support high levels of expression.

Authors:  N Y Jin; S Funahashi; H Shida
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

10.  Viral sequestration of antigen subverts cross presentation to CD8(+) T cells.

Authors:  Eric F Tewalt; Jean M Grant; Erica L Granger; Douglas C Palmer; Neal D Heuss; Dale S Gregerson; Nicholas P Restifo; Christopher C Norbury
Journal:  PLoS Pathog       Date:  2009-05-29       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.